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Abstract
A 72-year-old male was brought to the hospital following a
motorcycle crash and was admitted for multiple trauma man-
agement. His initial course of hospitalization was complicated
by mild hypoxemia and altered mental status. Respiratory
workup and imaging were consistent with SARS-CoV-2 pneu-
monia. He completed a five-day course of remdesivir and a
ten-day course of dexamethasone. Twenty days later, he de-
veloped a low-grade fever. His chest computerized tomogra-
phy (CT) showed gas and fluid containing parenchymal col-
lection in the anteromedial right middle lobe measuring up to
4.8 cm, most consistent with a pulmonary abscess. Antimi-
crobial treatment was started.
The patient became hypoxic and was intubated and mechan-
ically ventilated. Bronchoalveolar lavage fluid was positive
for galactomannan assay, a diagnostic marker for possible
aspergillosis. A repeat chest CT showed a cavitary lesion
with a positive air crescent sign, a common CT finding of in-
vasive pulmonary aspergillosis. The patient was diagnosed
with COVID-19-associated pulmonary aspergillosis and was
started on antifungal treatment. He improved clinically and
was successfully extubated.
Introduction
Bacterial and fungal superinfections are common com-
plications of viral pneumonia. The incidence varies
between hospitals. One prospective study reported
that 22% of the hospitalized COVID-19 patients expe-
rienced superinfections during their hospital stay. The
median time from their admission to superinfection
was 19 days.[1] The SARS-CoV-2 virus may affect the
length of stay and prognosis. The combination of se-
vere respiratory infections caused by SARS-CoV-2 or
influenza, with or without a severely weakened im-
mune system and vascular invasion of the airways, is
thought to compromise the mucosal clearing mecha-
nism and weaken its ability to protect the lungs.[2] This
may increase the severity of the respiratory infection,
prolong the duration of hospitalization, and worsen the
overall outcome. The following report summarizes a
case of COVID-19-associated pulmonary aspergillosis
(CAPA); IRB #20.0225.
Case report
A 72-year-old male with a history of essential hyper-
tension, hyperlipidemia, and gout was brought to the
emergency department following a motorcycle crash.
Radiologic reports determined no skull, chest, or pelvic
fractures. However, upon admission, he was found
to have multiple long bone fractures in his upper and
lower extremities. Chest X-ray was negative for pneu-
monia upon admission. He had a temperature of 96.7
°F, a heart rate of 86 beats/minute, a respiratory rate of
18 breaths/minute, blood pressure of 103/56 mmHg,
and an O2 saturation of 95% on 2 L of supplemen-
tal oxygen. A nasopharyngeal reverse transcriptase-
polymerase chain reaction (RT-PCR) swab was posi-
tive for SARS-CoV-2. His initial arterial blood gases
showed pH 7.33, pCO2 37.5 mmHg, pO2 325 mmHg, bi-
carbonate 20 mmol/L, and a base deficit of -3.5 nmol/L
while receiving an FiO2 of 100%.
On day 4 of hospitalization, he developed a low-grade
fever of 101.3 °F, along with a new mildly altered men-
tal status. The patient denied shortness of breath and
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Figure 1. Chest computed tomography of a patient with COVID-19-associated pulmonary aspergillosis with worsening pulmonary infiltrates
between admission (left) and hospital day 29 (right).
chest tightness but developed labored breathing with
increased oxygen requirements. Although his men-
tal status continued to decline over the following two
days, it was thought to be due to hypoxemia. He was
admitted to the intensive care unit (ICU) and started
treatment with 200 mg remdesivir, followed by a four-
day course of 100 mg remdesivir along with 6 mg of
dexamethasone daily for a total of 10 days. The pa-
tient completed his anti-COVID-19 regimen and was
weaned to high-flow O2 via an oxygen mask.
A repeat chest X-ray showed bibasilar infiltrates. His
hospital course was complicated by a persistent fever,
which in turn increased the suspicion of hospital-
acquired pneumonia.
On day 29 of hospitalization, the patient had a chest
computed tomography (CT), which showed an air-
fluid collection in his right middle lobe measuring 4.8
cm, consistent with a lung abscess (Figure 1). The
patient was started on vancomycin and piperacillin-
tazobactam. Serum galactomannan assay was nega-
tive, while bronchoalveolar lavage (BAL) galactoman-
nan was positive. His serum (1,3)-β-D-glucan was
<31 pg/mL (<80 pg/mL). He was started on 6
mg/kg voriconazole every 12 hours to cover inva-
sive pulmonary aspergillosis (IPA). After nine days of
voriconazole use, his liver enzymes increased. As-
partate aminotransferase increased to 124 U/L, ala-
nine aminotransferase increased to 40 U/L, and alka-
line phosphatase increased to 407 U/L. The voricona-
zole dose was decreased to 4 mg/kg every 12 hours,
and the transaminases were monitored. After 32 days
of voriconazole, the patient was switched to 200 mg
posaconazole every 8 hours to minimize the risk of hep-
atic toxicity. Despite the patient’s clinical improvement,
the liver enzymes continued to trend upward, and clin-
ical judgment dictated that the risk of continuing an-
tifungal medication outweighed the expected benefits.
Therefore, the posaconazole was stopped after a total
antifungal treatment of 35 days. Outpatient follow-up
was recommended to reassess the need for antifungal
medications.
Discussion
Secondary respiratory infections in patients with
COVID-19 are significant complications to recognize,
especially in critically ill patients admitted to the ICU.
Factors complicating the study of CAPA include the
novelty of the COVID-19 pandemic, the rapidly evolv-
ing number of new cases, and the lack of standardized
protocols for the diagnosis and management of cases.
Bronchoscopy is an aerosol-generating procedure, so
its use is limited in COVID-19 patients.[3] As a result,
the bronchial fluid galactomannan assay and (1,3)-β-D-
glucan cannot be performed for some patients despite
the high suspicion of CAPA.
CAPA is a complication following SARS-CoV-2 in crit-
ically ill patients with acute respiratory distress syn-
drome (ARDS); incidence rates of coinfection vary
between 8 and 33%.[4] In a study from the United
Kingdom National Mycology Reference Laboratory,
among 719 critically ill patients, the incidence of prob-
able/proven cases of CAPA was 5% and of possible
cases of CAPA was 15%.[4]
Aspergillus is a common mold, over 40 species of
which can infect humans. Aspergillus is ubiquitous
both indoors and outdoors, and its spores can eas-
ily reach the host’s alveoli.[5] For those who are im-
munosuppressed, breathing in Aspergillus conidia—a
type of spore produced at the tip of specialized fungal
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hyphae—can cause an infection in the lungs or sinuses,
spreading to other parts of the body.[5] The invasive na-
ture of this pathogen is propagated when the conidia
reach the host’s alveoli, germinate inside the respira-
tory tract, and activate neutrophil recruitment. In turn,
there is a massive influx of inflammatory cytokines, in-
cluding tumor necrosis factor-α (TNF-α). Immunocom-
petent hosts can clear these conidia and prevent inva-
sion of the alveoli.[5, 6]
The use of dexamethasone is a cornerstone of the
treatment of hypoxic respiratory failure in critically
ill patients with COVID-19 pneumonia, but corticos-
teroid use may increase the risk of developing IPA.[7–
9] A retrospective database review of 412 patients with
IPA in the ICU, excluding transplant, cancer, AIDS,
and neutropenic patients, found that 77% (n=315) of
the patients received high-dose corticosteroid therapy,
such as dexamethasone, during their hospital stay.[7]
Among 108 intubated patients with COVID-19 in the
ICU, 30 (28%) were diagnosed with probable CAPA be-
tween a median of 4 days (range 2–8 days) following
intubation to a median of 14 days (range 11–22 days)
from the first day of COVID-19 symptoms.[8] The only
factor associated with CAPA was prolonged steroid use
at a dosage higher than or equivalent to prednisone 16
mg/day for at least 15 days. Furthermore, in a system-
atic review performed in Basel, Switzerland, 85 patients
with CAPA in 22 studies were identified.[9] None of the
cases had immunosuppression due to organ transplant
or neutropenia, although 39 out of 85 patients received
corticosteroids as a part of the COVID-19 treatment.
The benefit of dexamethasone treatment to patients
with SARS-CoV-2 infection is believed to be due to
the anti-inflammatory effect of dexamethasone during
the cytokine storm and ARDS.[10, 11] However, dex-
amethasone also compromises the function of alveolar
macrophages, providing a greater opportunity for As-
pergillus conidia to germinate, resulting in an increased
risk of developing CAPA.
The respiratory epithelial structural damage in pa-
tients with ARDS following SARS-CoV-2 infection may
also contribute to the increased risk of developing
CAPA.[12] Respiratory viral infections damage the
lung epithelium by disrupting tight junctions among
epithelial cells.[13] Moreover, viral infections ham-
per ciliary clearance by respiratory epithelium.[14] To-
gether, these factors enable Aspergillus conidia to prolif-
erate and invade lung tissue while avoiding clearance.
Early diagnosis and treatment of CAPA are crucial to
predict and improve patient outcomes.[8] Bartoletti et
al. found that a diagnosis of CAPA was associated with
increased 30-day mortality from ICU admission, even
after adjusting for renal replacement therapy, and Se-
quential Organ Failure Assessment score at ICU ad-
mission.[8] The same study assessed mortality out-
comes of CAPA patients who underwent antifungal
treatment. A total of 53% (n=16) underwent antifun-
gal treatment, of whom 81% (n=13) underwent treat-
ment with voriconazole. Among patients with proba-
ble CAPA, those treated with voriconazole trended to-
wards a lower mortality.[15] These results demonstrate
the need for treatment of CAPA when clinically sus-
pected.
Conclusion
CAPA is a major complication of SARS-CoV-2 pneumo-
nia. It worsens the course of the disease, increases the
risk of mortality, increases the severity of the infection,
and prolongs the duration of hospitalization.[4, 8] The
use of dexamethasone and alveolar structural damage
caused by SARS-CoV-2 infection both play a role in fa-
cilitating the invasion of the pulmonary tissue and ves-
sels by Aspergillus.[11, 12] Therefore, early diagnosis is
critical for improved patient outcomes. Further studies
are required to establish a standardized algorithm for
early diagnosis and management of cases of CAPA.
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